Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 6 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1646 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to focus on its priority brands and emerging markets, GlaxoSmithKline (GSK) has agreed to divest 17 of its non-core consumer brands in the US and Canada to Prestige Brands for £426 M (US$661 M) in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS